The new version of the medical insurance drug list was officially launched on March 1, what are the

A few days ago, the National Health Insurance Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2020)". In this adjustment, 119 kinds of drugs were transferred in, 29 kinds of drugs were transferred out, and finally there were 2,800 kinds of drugs in the "Catalog", including 1,426 kinds of Western medicines and 1,374 kinds of Chinese patent medicines, and the proportion of Chinese and Western medicines was basically the same. The new version of the Catalogue will be officially implemented on March 1, 2021.

The adjustment of the national medical insurance catalogue is unprecedented, and it is the first attempt to negotiate the price reduction of the drugs in the catalogue. In the future, the annual adjustment of the medical insurance drug list will become the norm, which is expected to further expand the breadth and depth of medical security in terms of "cost performance", effectively reduce the economic burden of patients, and let the people enjoy the fruits of reform.

The National Health Insurance Administration said that a total of 162 drugs were negotiated for the adjustment of the "Catalogue", and 119 drugs were successfully negotiated, with a success rate of average price reductions for drugs that were successfully negotiated. Taking the most concerned anti-cancer drugs as an example, in 2018, the National Health Insurance Administration organized special access negotiations for anti-cancer drugs, and finally 17 drugs were successfully included in the catalogue through negotiations, and the agreement expired at the end of 2020. 14 exclusive drugs were renewed or renegotiated according to the rules, with an average reduction of more than 60% for individual first-line anti-cancer drugs.

When talking about the use of drugs for children, Ji Xiaohua, chief physician of the Department of Pediatrics of Xiyuan Hospital of the China Academy of Chinese Medical Sciences, said that a total of 7 pediatric drugs were included in the medical insurance negotiation, which fully took into account the safety and effectiveness of the drugs. The supplementary pediatric drugs are the most commonly used in clinical practice, and since pediatric outpatient respiratory and digestive diseases account for a large proportion, this adjustment of medication is specially included for these two diseases.

The National Health Insurance Administration estimates that most of the 119 new drugs are exclusive drugs that have been negotiated to achieve price reductions, and it is expected that the increased ** expenditure in 2021 will be basically the same as the space vacated by negotiations and drug transfers. On the other hand, from the perspective of patient burden, it is expected that the burden on patients will be reduced by about 28 billion yuan in 2021 through negotiated price reductions and medical insurance reimbursement.

Corresponding rectifications have been made for some drugs, and price reductions have also been adjusted for some medical equipment.

More than 100 drugs that were not previously covered by medical insurance have been included in the scope of medical insurance, and more than a dozen anti-cancer drugs have been added.

A lot of children's drugs have been added, including cold powder, fever medicine, etc., and 17 new cancer drugs have also been added, adjusting the first standards of many previous drugs.

In this list, 119 drugs are included in this list, and many drugs have been reduced in price, and then the new crown drugs have also been included in the medical insurance.

After the drug enters the national medical insurance drug list, it also obtains the qualification for medical insurance payment, forming the concept of "reimbursement" for the insured. Whether a drug is in the medical insurance drug list and whether it can be reimbursed greatly affects the doctor's choice of prescription and the patient's willingness to use it. Commonly used drugs for children's drugs and major diseases such as cancer, severe mental illness, hemophilia, diabetes, cardiovascular and cerebrovascular diseases have basically been included in the drug list or negotiated drug scope, effectively alleviating the clinical drug dilemma caused by the lack of adjustment of the catalog for nearly 8 years.

1. The adjustment of the new catalogue aims at the "four insistences", and strives to relieve everyone's worries about medical treatment for diseases. 2. There are new changes in the adjustment of the national medical insurance drug list this year, and the expression of appropriate preferences for special groups such as patients with rare diseases and children has attracted much attention. 3. The results of the new version of the medical insurance drug catalogue will be announced in November, focusing on the inclusion of drugs with high clinical value, high quality and reasonable medical needs.

The scope of declaration will be optimized, which can better improve the way of breeding meat, which is more convenient and safer, which is good for medical insurance.

A total of 2,709 drugs were included in the new version of the catalog, with 218 drugs transferred in and 154 drugs transferred out compared with the 2017 edition, a net increase of 64. 70 new drugs were included in the National Reimbursement Drug List through negotiations, and the average decreased.

Many new drugs involving cancer, rare diseases, and chronic diseases are included in the catalog, and the first record is low. Starting from January 1, 2020, insured persons can be reimbursed for a certain percentage of the drugs in the new version of the medical insurance drug list in accordance with the local medical insurance policy.

A few days ago, the National Healthcare Security Administration issued an announcement on the phased results of the expert review of the declared drugs that have passed the formal review for the adjustment of the National Medical Insurance Drug List in 2022

In accordance with the "2022 Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance", the National Health Insurance Administration organized experts to conduct a comprehensive review of the declared drugs that passed the adjustment form review of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022 (hereinafter referred to as the 2022 National Medical Insurance Drug Catalogue). At present, the expert review work has ended, and the announcement is as follows:

1. Each applicant enterprise can log on to the National Medical Insurance Service Platform (National Medical Insurance Drug Catalogue Adjustment Declaration" module (hereinafter referred to as the application module) to inquire about the expert review results.

2. For drugs whose evaluation results are "new to be negotiated", "new to be added to bidding", "to be negotiated for renewal" and "to be simply renewed", the corresponding enterprise will be in the "declaration module"** corresponding to the "confirmation letter template". Please fill in and affix the official seal as required and upload it to the "Declaration Module" before 17:00 on October 20, 2022, and send the original to the National Health Insurance Administration (subject to the postmark).

3. To confirm the participation in the negotiation and the drugs to participate in the bidding, the corresponding enterprise shall fill in and submit the corresponding "submission material template" in the "declaration module". Enterprises should ensure that the relevant data and materials submitted are complete, authentic and reliable, and send one copy of the paper version and one electronic version of the CD (the first volume of materials is provided in word and pdf version) to the National Health Insurance Administration before 17:00 on November 3, 2022 (subject to the postmark).

Please click "Details" in the "Negotiation Bidding Information" column to view the contents of the negotiation bidding reference drugs, negotiation main specifications and medical insurance payment scope determined by expert review.

4. If the evaluation result is "new to be negotiated" or "new to be added by bidding", it means that the drug has been included in the negotiation and bidding scope of the 2022 National Medical Insurance Drug Catalogue and has obtained the qualification for negotiation and bidding, which does not mean that the drug has been included in the 2022 National Medical Insurance Qinxingchai Drug Catalogue.

5. In order to ensure the smooth progress of the subsequent stage of the catalogue adjustment, before the official release of the 2022 National Medical Insurance Drug Catalogue, all applicant enterprises should not release any information about this adjustment.

The National Catalogue of Drugs for Basic Medical Care Qingxian Insurance, Work-related Injury Insurance and Maternity Insurance (Yuhanpai 2022) contains a total of 2,967 kinds of Western medicines and Chinese patent medicines, including 1,586 kinds of Western medicines and 1,381 kinds of Chinese patent medicines. The number of new 108 off-list drugs** decreased through negotiations, involving 23 clinical groups, including 56 chronic disease drugs (hypertension, diabetes, psychiatric diseases and other tumor drugs, 17 anti-infective drugs, 7 rare disease drugs, etc.); Among them, 22 are for children, 2 are for new crown **, and 2 are essential drugs for the country, further improving the level of drug security in key areas.

On June 29, 2023, the National Health Insurance Administration announced the "2023 Work Plan for the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue", and from July 1, the application for the adjustment of the medical insurance drug catalogue will be officially started. Drugs included in the "Encouraged Generic Drug List", drugs included in the "List of Drugs Encouraged to R&D and Application for the Elderly, Elderly and Children", as well as drugs for rare diseases, no longer set restrictions on the time of approval, no longer take new crown drugs as a separate drug declaration condition, and strengthen the supervision of the integrity of reporting enterprises.

<>**Drugs for special diseases in children, which are expected to be covered by medical insurance. With the continuous progress and development of social science and technology, children's overall immunity will decline, and they are more likely to get sick, and even individual children suffer from some special diseases. To ensure the physical health of children, many drugs for special diseases of children are expected to enter the medical insurance, and the maximum reimbursement of these consumption after entering the medical insurance is about 80%.

There are also rare drugs that are also expected to be covered by health insurance。In addition to the various diseases that people are familiar with in daily life, there are a very small number of groups suffering from very rare symptoms, which are not only difficult, but also very expensive, and it is difficult for ordinary families to afford them, so in this year's pharmaceutical negotiation process, these rare special drugs will hopefully enter the medical insurance to save more minority families, for example, the cost of a special drug for a rare disease is as high as 1.2 million yuan, after entering the medical insurance, The amount borne by each family may only be about 200,000 yuan to 300,000 yuan, although this money is still a lot for a family, but compared with the original actual ** relevant departments have really worked hard.

Some Western medicines are used for various cancers, and there is also hope that they will enter the medical insurance. With the acceleration of people's pace of life and the increase of life pressure, many people will have a variety of diseases in their bodies when they are old, and even have the risk of cancer.

The adjustment of the national medical insurance catalogue is about to start, and a total of 119 drugs have been added to the catalogue through this high adjustment, and 29 of the original catalogue have been transferred out, because of the impact of the epidemic, this year's ribavirin file injection and arbidol granules will successfully enter the medical insurance, and 17 kinds of anti-cancer drugs have been added, such as rivatinib.

It is used for some of the rarer drugs. There are also some medicines for ** special diseases. There are also drugs that are urgently needed in clinical practice.

There are also some medicines used for children's diseases. There are also some drugs that can be used for ** underlying diseases. There is hope that they can enter the medical insurance, and this kind of news is also Ji Yin makes people feel that the special fight hall is not excited, and it can also bring great convenience to everyone.

More rare disease drugs, children's drugs are very likely to enter the scope of medical insurance, and this year, China's medical insurance catalog has been adjusted, new children's drugs and generic drugs, so where is the future national chain, in terms of medical insurance benefits, there will be more people in the audience, so that more people can afford to see a doctor, and will no longer go to the doctor because of lack of money.

The new version of the National Medical Insurance Drug List will be implemented on January 1!

The new version of the National Medical Insurance Drug Catalogue adds 74 new drugs that are not included in the catalogue, including 67 exclusive drugs that have been negotiated and 7 non-exclusive drugs that have been directly transferred, among which the average price of the exclusive drugs that have been successfully negotiated has been reduced. Poke the link to view 74 new drugs added to the National Medical Insurance Catalog!

After the adjustment of the catalogue, the total number of drugs in the national medical insurance drug catalogue is 2,860, including 1,486 Western medicines and 1,374 Chinese patent medicines. The number of Chinese herbal decoction pieces in the catalogue has not been adjusted, and it is still 892.

The latest National Medical Insurance Drug List.

Can you find it in**?

The "National Medical Insurance Drug List Query" provided by the National Health Security Administration

The *** client applet is online!

Scan to query the national medical insurance drug list

Enter the name of the drug, select "Western Medicine", "Chinese Patent Medicine" or "Chinese Medicine Decoction Piece", and you can learn more about the drug, including the reimbursement category, medical insurance payment standard and other details!

The new version of the National Medical Insurance Drug Catalogue has added 74 off-list drugs, check it before buying drugs, and know it!

This service is provided by the National Health Security Administration, which is authoritative and reassuring.